Cargando…
Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325123/ https://www.ncbi.nlm.nih.gov/pubmed/33906297 http://dx.doi.org/10.31557/APJCP.2021.22.4.1063 |
_version_ | 1783731504824713216 |
---|---|
author | Lahmadi, Mohamed Beddar, Leila Rouibah, Amira Lyna Boumegoura, Ali Boufendi, Houda Temim, Asma Nini, Anissa Sellam, Feriel Satta, Dalila |
author_facet | Lahmadi, Mohamed Beddar, Leila Rouibah, Amira Lyna Boumegoura, Ali Boufendi, Houda Temim, Asma Nini, Anissa Sellam, Feriel Satta, Dalila |
author_sort | Lahmadi, Mohamed |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features. METHODS: We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected NSCLC samples using PCR followed by direct sequencing. RESULTS: The present study included 53 (91.4%) men and 5 (8.6%) women, with a median age of 59 (ranging from 44 to 94 years old). EGFR mutations were detected in 23 patients, with an overall rate of 39.6%. There were 21 (91.3%) cases with the exon-21 L585R single mutation and two (8.7%) with dual mutations of exon-19 deletions and L585R. EGFR mutations were more frequently found in patients with confirmed adenocarcinoma (14/27, 51.8%) than in non-adenomatous NCSCL subtypes (3/14, 21.4%; p=0.03). Furthermore, early stages of the disease were significantly associated with a higher rate of EGFR mutations (14/27, 51.8%) compared with those at advanced stage (5/21, 23.8%; p=0.02). There were no significant differences in EGFR mutation frequency by age, gender, or smoking status. CONCLUSION: We found that Algerian NSCLC patients exhibited a high rate of EGFR mutations, which was quite similar to that in Asians population rather than Caucasian patients. Thus, TKI-based treatments may be more beneficial for Algerian patients with NSCLC. Further studies using a large number of patients are required to confirm our preliminary findings. |
format | Online Article Text |
id | pubmed-8325123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-83251232021-08-06 Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer Lahmadi, Mohamed Beddar, Leila Rouibah, Amira Lyna Boumegoura, Ali Boufendi, Houda Temim, Asma Nini, Anissa Sellam, Feriel Satta, Dalila Asian Pac J Cancer Prev Research Article BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features. METHODS: We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected NSCLC samples using PCR followed by direct sequencing. RESULTS: The present study included 53 (91.4%) men and 5 (8.6%) women, with a median age of 59 (ranging from 44 to 94 years old). EGFR mutations were detected in 23 patients, with an overall rate of 39.6%. There were 21 (91.3%) cases with the exon-21 L585R single mutation and two (8.7%) with dual mutations of exon-19 deletions and L585R. EGFR mutations were more frequently found in patients with confirmed adenocarcinoma (14/27, 51.8%) than in non-adenomatous NCSCL subtypes (3/14, 21.4%; p=0.03). Furthermore, early stages of the disease were significantly associated with a higher rate of EGFR mutations (14/27, 51.8%) compared with those at advanced stage (5/21, 23.8%; p=0.02). There were no significant differences in EGFR mutation frequency by age, gender, or smoking status. CONCLUSION: We found that Algerian NSCLC patients exhibited a high rate of EGFR mutations, which was quite similar to that in Asians population rather than Caucasian patients. Thus, TKI-based treatments may be more beneficial for Algerian patients with NSCLC. Further studies using a large number of patients are required to confirm our preliminary findings. West Asia Organization for Cancer Prevention 2021-04 /pmc/articles/PMC8325123/ /pubmed/33906297 http://dx.doi.org/10.31557/APJCP.2021.22.4.1063 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lahmadi, Mohamed Beddar, Leila Rouibah, Amira Lyna Boumegoura, Ali Boufendi, Houda Temim, Asma Nini, Anissa Sellam, Feriel Satta, Dalila Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer |
title | Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer |
title_full | Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer |
title_fullStr | Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer |
title_full_unstemmed | Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer |
title_short | Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer |
title_sort | analysis of egfr mutation status in algerian patients with non-small cell lung cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325123/ https://www.ncbi.nlm.nih.gov/pubmed/33906297 http://dx.doi.org/10.31557/APJCP.2021.22.4.1063 |
work_keys_str_mv | AT lahmadimohamed analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT beddarleila analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT rouibahamiralyna analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT boumegouraali analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT boufendihouda analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT temimasma analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT ninianissa analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT sellamferiel analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer AT sattadalila analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer |